Regorafenib, as a sorafenib derivative and pan-TKI of several kinases involved in tumor angiogenesis (VEGFR1–3 and TIE2), oncogenesis (KIT, RET, RAF1, and BRAF genes), the tumor microenvironment (PDGFR and FGFR), and tumor immunity (colony-stimulating factor 1 receptor), is recommended in the newest NCCN guideline for testing in future clinical trials due to a phase II parallel trial harboring a notable outcome (64, 64). This evidence concerns the gene BRAF and neoplasm.